Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$28.84 USD

28.84
16,107,978

+0.39 (1.37%)

Updated Oct 28, 2024 01:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (36 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AstraZeneca/Merck's Lynparza Get FDA Nod for Prostate Cancer

by Zacks Equity Research

FDA approves AstraZeneca (AZN)/Merck's (MRK) PARP inhibitor Lynparza for HRR gene-mutated metastatic castration-resistant prostate cancer. The approval was based on data from the phase III PROfound study.

Moderna Declines on Skepticism on Coronavirus Vaccine Data

by Zacks Equity Research

Moderna (MRNA) shares decline following a report raising questions on clinical data announced earlier this week related to its coronavirus vaccine.

J&J to Stop Sale of Talc-Based Baby Powder in North America

by Zacks Equity Research

J&J (JNJ) faces thousands of lawsuits, which claim that its talc-based products, primarily its baby powders, cause cancer.

Glaxo's Long-Acting HIV Injection Effective Than Daily Pills

by Zacks Equity Research

Glaxo's (GSK) long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral pills.

Ritujay Ghosh headshot

5 Biotech Stocks in Focus as Race for Coronavirus Vaccine Heats Up

by Ritujay Ghosh

Drugmakers and biotech companies are initiating development of drugs, vaccines and therapies for COVID-19 and substantial progress has been made over the past month.

Neena Mishra headshot

Moderna Soars: Biotech ETFs in Focus

by Neena Mishra

Positive data on early-stage coronavirus vaccine trial sent Moderna shares surging.

Deciphera (DCPH) Secures Early FDA Nod for GIST Drug Qinlock

by Zacks Equity Research

The FDA lends a speedy nod to Deciphera's (DCPH) Qinlock for the treatment of fourth-line gastrointestinal stromal tumors. The approval comes three months ahead of schedule.

Clovis' (CLVS) Rubraca Gets FDA Approval for Prostate Cancer

by Zacks Equity Research

Clovis' (CLVS) PARP inhibitor, Rubraca, receives approval from the FDA as monotherapy to treat BRCA-mutant metastatic castration-resistant prostate cancer.

Sarepta Surges on Rival Pfizer's DMD Gene Therapy Study Data

by Zacks Equity Research

Sarepta (SRPT) investors cheer the announcement of Pfizer's early-stage gene therapy study data, which seems to trail Sarepta's gene therapy candidate, SRP-9001's performance.

Pfizer Reports Efficacy & Safety Data on DMD Gene Therapy

by Zacks Equity Research

Pfizer's (PFE) new phase Ib data on its investigational gene therapy, PF-06939926 in ambulatory boys with DMD support advancement to a pivotal phase III study.

Neena Mishra headshot

Healthcare Tech & Robotics ETFs in Focus amid COVID-19 Crisis

by Neena Mishra

The pandemic will forever transform our lives; here are some areas that may benefit.

The Zacks Analyst Blog Highlights: LLY, AZN, PFE, SNY and BMY

by Zacks Equity Research

The Zacks Analyst Blog Highlights: LLY, AZN, PFE, SNY and BMY

Sweta Jaiswal, FRM headshot

Biotech ETFs to Gain From Latest Advancements in Cancer Drugs

by Sweta Jaiswal, FRM

The rising incidence of cancer cases has encouraged several major pharmaceutical and biotech players to invest substantially in the developments of drugs.

Kinjel Shah headshot

Drug Sector Highly Resilient Amid Coronavirus Mayhem: 5 Picks

by Kinjel Shah

Here we highlight five large drugmakers that can be added to one's portfolio amid the coronavirus crisis.

Zacks.com headshot

Biotech Companies Lead Search for Coronavirus Vaccine: 4 Winners

by Zacks.com

Although a vaccine is yet to be developed, many companies have already started ramping up manufacturing process of the experimental vaccine candidates they are working on.

Sweta Jaiswal, FRM headshot

Novavax Soars on Coronavirus Vaccine Funding: ETFs to Gain

by Sweta Jaiswal, FRM

Novavax received funding for the coronavirus vaccine and also delivered better-than-expected Q1 results resulting in a stock rally in yesterday's trading session.

Mylan (MYL) Beats on Q1 Earnings on Coronavirus-Led Stockpiling

by Zacks Equity Research

Mylan (MYL) beats on Q1 earnings but misses on sales.

Kinjel Shah headshot

Pharma Stock Roundup: Q1 Earnings of BMY, NVO, Coronavirus Update From PFE, RHHBY

by Kinjel Shah

Novo Nordisk (NVO) and Bristol-Myers (BMY) announce Q1 results. Pfizer (PFE), Roche (RHHBY) and Lilly (LLY) provide update on their coronavirus-related research efforts.

Nektar's (NKTR) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Nektar (NKTR) reports encouraging first-quarter 2020 results. The company continues to progress with its pipeline candidates.

Bristol-Myers' (BMY) Q1 Earnings & Sales Beat Estimates

by Zacks Equity Research

Bristol-Myers (BMY) beats on earnings and sales in the first quarter on strong performance of Revlimid and Eliquis.

The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Regeneron Pharmaceuticals, Moderna and Sanofi

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Regeneron Pharmaceuticals, Moderna and Sanofi

Neena Mishra headshot

Biotech ETFs Poised to Benefit From Coronavirus

by Neena Mishra

Rising investor interest in coronavirus related stocks will benefit these ETFs

Jazz Pharma (JAZZ) Misses on Q1 Earnings & Sales, Cuts View

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) reports lower-than-expected first-quarter 2020 earnings and revenues. It lowers its guidance for 2020. Shares drop.

5 Stocks to Buy as Coronavirus Vaccine in Human Trails Ramp Up

by Zacks Equity Research

As drug makers race to develop vaccine to fight coronavirus, we shortlist five stocks that are poised to grow on progress in clinical trials.

Stock Market News for May 6, 2020

by Zacks Equity Research

Benchmarks ended higher on Tuesday after healthcare stocks jumped on reports of progress in coronavirus vaccine.